There wasn't anything in Novo Nordisk's (NYSE: NVO) second-quarter results to get too excited about, and it appears the company will continue to face pricing pressure for its diabetes drugs from payers next year as well.MetricQ2 2018Continue reading
newsfeedback@fool.com (Brian Orelli), The Motley Fool
Tue, 08/14/2018 - 1:22pm
There wasn't anything in Novo Nordisk's (NYSE: NVO) second-quarter results to get too excited about, and it appears the company will continue to face pricing pressure for its diabetes drugs from payers next year as well.MetricQ2 2018Continue reading